On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject administration. MDR-001 is for the treatment of indications such as obesity and type 2 diabetes.
Shanghai Medicilon Inc. (Medicilon), as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.
From "powerful" hypoglycemic drugs to "miracle" weight-loss drugs, the huge market space of GLP-1 is attracting more attention. As a one-stop biopharmaceutical preclinical research and development service platform, Medicilon has already established a presence in the GLP-1 field, and can provide clients with GLP-1 drug discovery, GLP-1 pharmaceutical research (API process development & preparation), GLP-1 pharmacodynamic research, GLP-1 pharmacokinetic evaluation and GLP-1 safety evaluation.
As of the end of May 2023, Medicilon has successfully assisted 7 GLP-1 drugs to be approved for clinical trials, of which 3 GLP-1 drugs were approved by NMPA/FDA at the same time. There was also another GLP-1 drug was approved by the US FDA, China NMPA and Australia TGA. In addition, there are multiple GLP-1 projects are ongoing under schedule. Relying on rich R&D experience and successful cases, Medicilon has won the trust and affirmation of the clients again and again.
Medicilon congratulates the GLP-1RA small molecule oral drug of MindRank successfully completed the administration of the first subject in clinical phase I. It is hoped that in the next clinical practice, GLP-1RA can send good news to both diabetic and obese patients. Medicilon will also actively embrace new technologies to speed up the new drug development process.
Relevant
news
marketing@medicilon.com
